Based on Luminex technology platform, Creative Proteomics provides analysis services for key targets of ROS1 signaling pathway.
The ROS1 gene is located in the q21 region of chromosome 6. The full-length cDNA contains 44 exons and encodes 2347 amino acids. The insulin receptor is a member of the RTKs family ROIS1 and ALK. 77% of the tyrosine kinase domains are identical. Therefore, the ALK small molecule inhibitor crizotinib has obvious curative effect in the treatment of NSCLC with fusion mutation of ROS1. In terms of pathogenic mechanism, despite the lack of suitable ligands or small molecule activators for ROS1 activation, the EGFR-ROS1 chimeric protein expression technology constructed using point mutations and EGFR extracellular receptor parts has been proved that ROS1 receptor tyrosine Kinases are involved in the activation of multiple downstream signal transduction pathways, including RAS-RAF-MEK-ERK, PI3K-AKT-mTOR and JAK-STAT3 pathways, which are related to tumor cell proliferation, survival and metastasis.
ROS1 is a proto-oncogene and is highly expressed in a variety of tumor cell lines. ROS1 is one of the family members of the tyrosine kinase insulin receptor. The encoded protein is a type I intramembrane protein with tyrosine kinase activity, which can be used as a receptor for growth factors or differentiation factors.
ROS1 can activate signal pathways related to cell differentiation, proliferation, growth and survival, including PI3K-AKT-mTOR pathway. ROS1 can activate downstream signaling pathways by regulating the phosphorylation of downstream pathway proteins, such as PTPN11 (activator of PI3K-mTOR pathway), AKT1, MAPK1, and STAT3 transcription factors.
The common pathogenic mutation of ROS1 gene is gene rearrangement. The resulting ROS1 fusion protein will become a continuously activated tyrosine kinase, which will activate the signals of its downstream pathways, which will cause cell overgrowth and proliferation.
At present, in the treatment of ROS1 fusion gene-positive NSCLC, crizotinib and entricinib have been approved for marketing, and ceritinib and lauratinib have been recommended by NCCN guidelines. The new ROS1-TKI is under development and will provide further information. There are many clinically effective drug options, and there will be more clinical treatment options for patients with clinical ROS1 fusion gene positive in the future.
We provide Luminex technology for ROS1 signaling pathway analysis.
Luminex technology is a multifunctional liquid phase analysis platform developed on the basis of colored microspheres, laser technology, applied fluidics and high-speed digital signal processing technology. The core is to encode polypropylene microspheres or magnetic microspheres with fluorescent dyes. By adjusting the different ratios of the two fluorescent dyes, up to 100 microspheres with different fluorescence spectra can be obtained. Antigen-antibody, enzyme-substrate, ligand-receptor binding reactions and nucleic acid hybridization reactions are performed on microspheres with different fluorescence encoding. Qualitative and quantitative analysis by laser detection of microsphere coding and reporter fluorescence separately.
ROS1 gene is a kind of proto-oncogene, and chromosome rearrangement is the primary mechanism of ROS1 activation. ROS1 can activate signaling pathways related to cell differentiation, proliferation, growth and survival. ROS1 signaling pathway is widely used in medical research.
In addition to Luminex Multiplex Assay, Enzyme-linked immunosorbent assay (ELISA), Flow cytometry (FACS analysis) technology can also be provided to meet other customer needs.
Creative Proteomics has developed a signal pathway target detection platform. We are not limited to providing ROS1 signal path detection services, but can also provide other signal path detection services. If you want to detect other targets, please contact us and we will customize the service for you. Look forward to working with you.